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Aim To describe our experience in the clinical application 
of extracorporeal life support (ECLS) and analyze whether 
ECLS leads to acceptable clinical outcomes in patients with 
cardiac failure.
Methods Data from clinical database of University Hospi-
tal Center Zagreb, Croatia, on 75 patients undergoing ECLS 
support from 2009 to 2014 due to cardiac failure were ret-
rospectively analyzed. Outcomes were defined as proce-
dural and clinical outcomes. ECLS as a primary procedure 
and ECLS as a postcardiotomy procedure due to inability 
to wean from cardiopulmonary bypass were analyzed.
Results ECLS was used in 75 adult patients, and in 24 
(32%) of those procedural success was noted. ECLS was 
implemented as a primary procedure in 36 patients and 
as a postcardiotomy procedure in 39 patients. Nine out of 
39 (23.08%) patients had postcardiotomy ECLS after heart 
transplantation. Bleeding complications occurred in 30 
(40%) patients, both in primary (11/36 patients) and post-
cardiotomy group (19/39 patients). ECLS was established 
by peripheral approach in 46 patients and by central can-
nulation in 27 patients. In 2 patients, combined cannula-
tion was performed, with an inflow cannula placed into 
the right atrium and an outflow cannula placed into the 
femoral artery. Eleven patients treated with peripheral ap-
proach had ischemic complications.
Conclusion ECLS is a useful tool in the treatment of pa-
tients with refractory cardiac failure and its results are en-
couraging in patients who otherwise have an unfavorable 
prognosis. Patient outcomes may be further improved by 
technological advances, more clinical experience in appli-
cation of the technique, careful patient selection, and mul-
tidisciplinary approach in patient management.
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The idea of extracorporeal life support (ECLS) became a re-
ality with the introduction of the heart-lung machine by 
Gibbon in 1954 (1). However, only in 1971 the first success-
ful extracorporeal membrane oxygenation treatment was 
described (2). Since then continuous technological im-
provements have led to the growing interest in this type 
of treatment (3).
ECLS may significantly improve the level of patient care in 
patients with acute and chronic heart failure. It is an ad-
vanced form of treatment and the patient management is 
carried out by a multidisciplinary team of cardiac surgeons, 
anesthesiologists, and cardiologists.
There are two main groups of indications for ECLS: those 
not related and those related to cardiac surgery. Primary 
ECLS procedures are not related to cardiac surgery but 
to acute cardiorespiratory failure arising from underlying 
cardiac disease. Postcardiotomy ECLS procedures may be 
considered as a secondary procedure and are directly re-
lated to cardiac surgery procedures. These procedures 
are indicated after cardiac surgery procedures when pa-
tients cannot be weaned from cardiopulmonary bypass or 
when there is low cardiac output syndrome in the early 
postoperative phase. Postcardiotomy cardiogenic shock 
occurs in up to 6% of cardiac operations (4-6), with only 
25% of those patients surviving to hospital discharge (4). 
Therefore, postcardiotomy cardiogenic shock is one of the 
most difficult and resource-consuming conditions, as it is 
associated with particularly high mortality rates. Since the 
risk profiles of patients scheduled for cardiac surgery pro-
cedures are continuously worsening, one may expect an 
increase in the number of patients requiring ECLS peri-
operatively. Although these patients have only 25% of sur-
vival to hospital discharge (4), one should be aware that 
they would have nearly 100% mortality if they were not 
placed on ECLS. Although early ECLS results for postcar-
diotomy cardiogenic shock were found to be poor (5,7), 
they have been improved by continuous technological ad-
vances (5,8-10). Primary ECLS procedures may also play a 
significant role in cardiac surgery patients. In general, ECLS 
restores body perfusion and allows different treatment 
modalities. This may help optimize a patient’s clinical con-
dition while waiting for a heart transplant. If a patient is 
not considered a suitable candidate for a heart transplant, 
ECLS may provide a bridge to long-term mechanical cir-
culatory support. However, if ECLS is intended to bridge 
a patient to recovery (for instance in patients with acute 
myocarditis), then ECLS support may be considered as a 
treatment per se.
ECLS may be used as either; 1) bridge to recovery, 2) 
bridge to transplant, 3) bridge to decision, or 4) bridge to 
intermediate or long term support. “Bridging concept” is 
important because a lack of exit strategy (eg, reason for 
bridging) may actually suggest a possible contraindica-
tion for ECLS.
ECLS may play a significant role in patients with acute car-
diogenic shock prior to scheduled cardiac surgery proce-
dures such as intermediate to long term mechanical cir-
culatory support, heart transplant, or other cardiosurgical 
procedures depending on the preexisting condition.
Preoperative patient optimization using ECLS improves 
the outcomes of the level 1 Interagency Registry for Me-
chanically Assisted Circulatory Support (INTERMACS) pa-
tients receiving a permanent ventricular assist device (11). 
This “bridge-to-bridge” concept consisted of preoperative 
stabilization of level 1 INTERMACS patients using ECLS a 
few days prior to ventricular assist device implantation. 
ECLS significantly improved renal, hepatic, and pulmonary 
functions (11).
In addition to this, preoperative ECLS support may sig-
nificantly improve outcomes in patients presenting with 
acute myocardial infarction (AMI) complicated with ven-
tricular septal defect (VSD) and cardiogenic shock (12). Pre-
operative ECLS provided hemodynamic support, ensured 
end-organ perfusion, helped the myocardium to recover 
and allow scar tissue to be formed by reducing sheer forc-
es, thus leading to more favorable outcomes (12).
For both primary and postcardiotomy indications, our 
team generally prefers combined support to the heart 
and lungs (ECLS) rather than isolated mechanical circu-
latory support to the failing heart. ECLS can be implant-
ed bedside, providing support to both the heart and the 
lungs simultaneously. Nowadays ECLS is available in many 
centers that do not perform ventricular assist device im-
plantation. In such centers, patients should be preoper-
atively stabilized and transferred on support to tertiary 
care centers for further treatment. To facilitate this pro-
cess, it would be necessary to establish an ECLS network 
with ECLS centers cooperating with tertiary centers that 
perform long term mechanical circulatory support, heart 
transplant, as well as complex surgical corrections. In this 
article, we describe our experience in the clinical appli-
cation of extracorporeal life support (ECLS) and aim to 
analyze whether ECLS leads to acceptable clinical out-
comes in patients with cardiac failure.
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MeTHoDS
ECLS was introduced at the Department of Cardiac Sur-
gery, University Hospital Center Zagreb in 1987. From 
1987 until 1995 only 12 patients were supported with 
MCS (ECLS 6 patients, LVAD 6 patients) but only 3 survived 
(1 patient on ECLS and 2 patients on LVAD). The mechani-
cal circulatory support (MCS) program was established in 
2008. Upon commencement of this program, a patient 
database was constructed, with anonymized and coded 
patients’ records.
This study presents retrospective analysis of data collected 
from 2009 to 2014, and it was approved by the University 
of Zagreb School of Medicine Ethics Committee.
Typical clinical scenarios for ECLS initiation were as fol-
lows: postcardiotomy cardiac failure, acute exacerbation 
of chronic severe heart failure, acute heart failure due to 
myocardial infarction, and cardiac arrest requiring cardio-
pulmonary resuscitation (CPR). Whenever possible, ECLS 
management was in line with the guidelines provided by 
ECLS working group (10).
Patients were classified according to INTERMACS registry 
(13). We defined outcomes as procedural and clinical out-
comes. A procedural outcome was considered as success 
if ECLS successfully bridged the patient to recovery, long-
term mechanical circulatory support, or heart transplant. 
Therefore, procedural success was defined as adequate 
employment of intentional strategy for ECLS. A proce-
dural outcome was considered as failure if ECLS did not 
achieve the previously defined target. Procedural success 
may ultimately result in adverse outcomes such as death, 
but procedural failure is inevitably associated with adverse 
outcomes. Clinical outcomes were defined as the follow-
ing conditions after 30 days follow up: alive, alive on sup-
port, and dead.
Implantation technique
ECLS was established by either central or peripheral ap-
proach depending on the underlying pathology. For prima-
ry ECLS procedures, a femoral route was preferred. The first 
modality for cannula insertion was Seldinger technique. 
In case of failed attempts of Seldinger technique, surgical 
exploration of the femoral vessels was performed. Postcar-
diotomy ECLS was established via a median sternotomy. 
Central cannulation sites were the right atrium for inflow 
cannula and the ascending aorta for outflow cannula.
Components of the eCLS circuit
The organization of ECLS was an integral part of the insti-
tutional algorithm on the device use and the type of sup-
port selection (Figure 1). Several components of the ECLS 
circuit are mandatory to initiate ECLS support. In brief, the 
ECLS circuit consists of an inflow and outflow cannulas, 
blood pumping device, and oxygenator. The following 
centrifugal pumps were used for blood pumping: Maquet 
Rotaflow centrifugal blood pump (Maquet Cardiovascular 
LCC, San Jose, CA, USA), Medtronic Bio-Medicus centrifugal 
pump (Medtronic Inc, Minneapolis, MN, USA), and Levit-
ronix Centrimag (Levitronix, Boston, MA, USA). Applied hol-
low fiber oxygenators were Maquet Quadrox and Euroset, 
as well as Medtronic IE 4500 flat sheet type oxygenator in a 
few cases. Biocompatible surface coating lines were used.
Anticoagulation protocol
All patients in a non-operative setting (primary proce-
dures) received a bolus dose of 50-100 IU/kg unfraction-
ated heparin (UFH) before cannulation, and the dose was 
modified based on patients’ pre-ECLS coagulation sta-
FIGure 1. Mechanical circulatory support at the Department of Cardiac 
Surgery, university Hospital Center Zagreb. Device selection algorithm. 
MCS – mechanical circulatory support; VAD – ventricular assist device; 
eCLS – extracorporeal life support; PVAD – paracorporeal ventricular assist 
device.
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tus and tendency to bleed. When activated clotting time 
(ACT) dropped below 300 s, a continuous UFH infusion 
was initiated at a rate of 10-20 IU/kg/h. In the postcardioto-
my setting, a bolus dose was required only if heparin was 
already fully reversed by protamine. Furthermore, a con-
tinuous UFH infusion at a rate of 10 UI/kg/h was usually 
initiated after 24 hours (and/or when the chest tube drain-
age was less than 4 mL/kg/h). The UFH infusion was then 
adjusted based on the results of anticoagulation monitor-
ing. These included activated partial thromboplastin time 
(aPTT – measured every 8 hours, with the target value 1.5-
2.5 × normal), ACT (measured every 4 hours, with a target 
value of 180-200 s), and anti Xa level (target value 0.4-0.7 
IU/mL). Standard laboratory tests were obtained twice dai-
ly and their values were maintained at near normal values 
(hematocrit >0.30, platelets >100 × 109/L, fibrinogen >2 
g/L, international normalized ratio (INR) 0.8-1.1, antithrom-
bin III (ATIII)>60%). However, since most thomboembolic 
and hemorrhagic events occur despite standard laborato-
ry tests being within the reference ranges (14), evaluation 
of viscoelastic properties of blood clots was performed us-
ing rotational thromboelastometry on a daily basis (14). In 
patients with clinical suspicion to heparin-induced throm-
bocytopenia, fondaparinux (0.07-0.1 mg/kg daily, with anti 
Xa level target peak value of 1.0-1.2 IU/mL) was used in-
stead of UFH.
Weaning protocol
Usually, the first evidence of myocardial recovery is in-
creased pulsatility of an arterial waveform. If this is accom-
panied by an improvement in echocardiographic appear-
ance of cardiac function and the absence of compromised 
pulmonary blood oxygenation, the patient is considered 
eligible for an ECLS weaning trial (15). Before the wean-
ing trial was undertaken, inotropes/vasopressors of choice 
(dobutamine, epinephrine, milrinone, levosimendan, nor-
epinephrine) were administered in moderate doses, vol-
ume status was optimized (best guided by echocardiog-
raphy), and ACT was targeted to at least 220 s (16). While 
ECLS flow was decreased in increments by 20% every few 
hours, echocardiographic, hemodynamic, and laboratory 
parameters were constantly evaluated. Flow was reduced 
in a stepwise manner to 1-1.5 L/min. If the patients were 
not demonstrating any signs of hemodynamic compro-
mise (stabile arterial blood pressure, adequate cardiac out-
put, mixed venous saturation (O2)>60%, central venous 
pressure <12 mm Hg, acceptable acid base status, lactate 
<3), they were usually weaned form ECLS and the cannu-
las were removed. However, if they did not tolerate the 
proposed decrease in mechanical support, the flow was 
restored to a higher value. Occasionally weaning off me-
chanical support was not possible, and bridging to ventric-
ular assist device or heart transplant was considered.
reSuLTS
From 2009 to 2014, 133 adult patients underwent mechan-
ical circulatory support with 165 mechanical circulatory 
support procedures performed (Figure 2). Several patients 
underwent multiple procedures. ECLS was used most fre-
quently – in 75 adult patients, 53 of whom (70.67%) were 
INTERMACS level 1 patients and 22 (29.33%) were INTER-
MACS level 2 patients (Table 1).
Single ECLS procedures were performed in 59 (78.7%) pa-
tients. ECLS procedures that were part of a multi-procedur-
al MCS treatment were performed in 16 patients (21.3%). 
All 16 patients were upgraded to longer-term mechanical 
circulatory support procedures. Of those, 7 patients un-
derwent left ventricular assist device implantation (3 Heart 
Mate II and 4 Levitronix Centrimag), 6 were placed on right 
ventricular assist device, and 3 were placed onto biventric-
ular support (1 patient on Thoratec pVAD and 2 patients on 
Levitronix Centrimag).
ECLS was implemented as a primary procedure in 36 pa-
tients and as a postcardiotomy procedure in 39 patients. 
FIGure 2. The number of extracorporeal life support (eCLS) 
procedures performed per year.
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Nine out of 39 (23.08%) patients had postcardiotomy ECLS 
after heart transplantation. The rest of postcardiotomy pro-
cedures were performed after heart valve surgery – one or 
more valves (15 patients), coronary artery surgery (7 pa-
tients), surgery for aortic dissection (1 patient), surgery for 
postinfarction ventricular septal defect (4 patients), Heart 
Mate 2 implantation (1 patient), and Bentall procedure (2 
patients). It is very important to notice that 11 heart trans-
plant patients were treated with ECLS as a primary proce-
dure. Of these, 6 were bridged with ECLS to heart trans-
plant. In summary, 20 patients from the heart transplant 
program were treated with ECLS support (Table 2).
Bleeding events occurred in 30 (40%) patients, both in pri-
mary (11/36 patients) and postcardiotomy group (19/39 
patients). Characteristics of bleeding events varied be-
tween patients. In general, such events occurred in the 
form of excessive mediastinal bleeding requiring surgi-
cal re-exploration, bleeding related to cannulation site 
in femoral arteries, retroperitoneal bleeding due to can-
nula misplacement, gastrointestinal bleeding, and bleed-
ing from the nasopharynx requiring surgical tamponade. 
Cardiac decompression due to left ventricular distention 
while on ECLS support was performed in 4 out of 75 pa-
tients (5.3%).
Peripheral cannulation was performed in 46 and central 
cannulation in 27 patients. Combined approach was per-
formed in 2 patients, with an inflow cannula placed into 
the right atrium and an outflow cannula placed into the 
femoral artery. In patients with peripheral approach, isch-
emic complications occurred in 11 cases. Three out of 11 
patients with vascular complications developed gangrene 
with diffuse lower limb ischemia.
DISCuSSIon
ECLS is a useful tool in the treatment of patients with refrac-
tory cardiac failure. Patients on ECLS (17) show improved 
outcomes, as well as favorable long-term outcomes and 
good quality of life of survivors (17). However, ECLS is re-
lated to a considerable rate of complications that require 
comprehensive and multidisciplinary management.
We used ECLS in 75 adult patients and procedural success 
was noted in 32%. Bleeding was the major complication, 
which occurred in 40% patients.
Despite appropriate ECLS, a certain number of patients 
develop left ventricular edema (18). We found that cardi-
ac decompression due to left ventricular distention while 
on ECLS was performed in 4 out of 75 patients (5.3%). In 
TABLe 1. Baseline demographics, clinical characteristics, and 
surgery data*†
Demographic data All patients (n = 75)
Age (years)  58 (49-65)
Men  47 (63)
Women  28 (37)
Body weight (kg)  78 (72-87)
Body height (cm) 171 (166-178)
BMI (kg/m2)  26 (24-30)
BSA (m2)   1.9 (1.8-2.1)
Clinical characteristics
Primary ECMO  36 (48)
Postcardiotomy ECMO  39 (52)
INTERMACS 1  52 (69)
INTERMACS 2  23 (31)
INTERMACS 3 and above   0 (0)
Surgery data
LA venting to ECMO “inflow”   4 (5)
Re-exploration for bleeding  30 (40)
Implantation between 2009 and 2011  23 (31)
Implantation between 2012 and 2014  52 (69)
*Abbreviations: BMI – body mass index; BSA – body surface area; 
eCMo – extracorporeal membrane oxygenation; InTerMACS - 
Interagency registry for Mechanically Assisted Circulatory Support; 
LA – left atrium.
†Data are presented as medians and interquartile ranges. Categorical 
variables are shown as absolute numbers with percentages.
TABLe 2. Procedural and clinical outcomes. Patients were divided according to type of procedure
outcome, n (%) Primary procedure n = 36 Postcardiotomy procedure n = 39 Total procedures n = 75
Procedural:
success 12 (33) 12 (31) 24 (32)
failure 24 (67) 27 (69) 51 (68)
Clinical:
alive  8 (22) 11 (28) 19 (25)
alive on support  4 (11)  1 (3)  5 (7)
dead 24 (67) 27 (69) 51 (68)
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these patients, a left atrial vent was placed through the 
right upper pulmonary vein and connected via a “Y” con-
nector to the tubes connected to the inflow cannula. This 
measure requires a sternotomy, but there is evidence that 
minimally invasive approach for cardiac decompression is 
feasible. Percutaneous transseptal left atrial decompres-
sion (19) and subxiphoid surgical decompression of the 
left ventricle (20) have already been described. A solution 
to avoid high-risk septostomy or surgical venting may be a 
percutaneously inserted ventricular assist device (Impella; 
Abiomed, Aachen, Germany) (21). In addition to this, gen-
eral measures should be considered to prevent left ven-
tricular distension on ECLS, such as afterload reduction, the 
use of inotropes, eg, epinephrine, calcium sensitizer levo-
simendan, arterial vasodilators, avoidance of volume over-
load, and hemofiltration. Aortic valve insufficiency and 
inadequate venous drainage may precipitate ventricular 
distention on ECLS (18).
Even though ECLS has been successfully used for well over 
the 30 years, the anticoagulation management in these 
patients remains controversial. The contact between blood 
and nonbiologic surface of an extracorporeal circuit pro-
vokes a massive acute response leading to the activation 
of both procoagulant and anticoagulant components and 
their subsequent consumption. The use of a systemic an-
ticoagulant drug is mandatory in order to prevent the de-
velopment of thromboembolic events, however it is chal-
lenging to balance its effect against the risk of bleeding 
(22). The preferred anticoagulation agent in the majority 
of ECLS centers is UFH, while direct thrombin inhibitors are 
seldom primarily used (16).
In this study, bleeding events occurred in 30 (40%) patients. 
Bleeding events are common in patients on ECLS support 
and may stem from the cannula insertion sites, especial-
ly the artery. Additionally, bleeding may occur spontane-
ously (intracranial and gastrointestinal bleeding) or may be 
related to minor interventions (23). Even diffuse intraop-
erative bleeding coupled with massive transfusion require-
ments leading to delayed chest closure may be considered 
as a bleeding event. Excessive bleeding and massive trans-
fusions may affect up to 80% of patients on ECLS support 
(24). Since these patients are thrombocytopenic and have 
consumption coagulopathy, we strongly suggest point-of-
care monitoring of hemostasis using thromboelastometry 
and platelet function testing (25). In our center, we per-
form thromboelastometric measurements on a daily basis 
for the first seven days following ECLS procedure. Prior to 
surgical intervention, it is of utmost importance to search 
for any hemostatic disorders and treat them selectively us-
ing rotational thromboelastometry (25).
ECLS support has a very important role in cardiac surgery 
patients who are unable to wean from cardiopulmonary 
bypass (CPB). The prevalence of postcardiotomy cardio-
genic shock ranges from 0.2 to 6% (4). Failure to wean from 
CPB remains the most common indication for ECLS in car-
diac failure. It is noteworthy that for postcardiotomy car-
diogenic shock, the survival rate was only 25% even with 
the use of a ventricular assist devices (26,27). Since postcar-
diotomy cardiogenic shock may mandate combined heart 
and lung support, we advise the use of ECLS, although 
there is scarce evidence on the usefulness of ECLS for post-
cardiotomy cardiogenic shock treatment and the studies 
are limited by a small number of patients and retrospec-
tive data collection. Nevertheless, survival rates ranging 
from 16%-76% suggest that it might be a useful tool in this 
type of treatment (5,6,28-32). These results may be further 
improved by timely application (4). Our survival rate was 
30.76%. In addition, clinical decision making should be 
guided by a model that predicts poor outcomes after post-
cardiotomy. However, to develop such a model, registries 
of data pooled from all centers should be established. Such 
approach could compensate for the lack of publications 
reporting poor outcomes and lead to meaningful conclu-
sions based on “real-world” results.
In our study, 9 out of 39 (23.08%) patients received post-
cardiotomy ECLS after heart transplantation. This propor-
tion is similar to 19% reported by ELSO registry. In addition, 
11 patients with heart transplants received primary ECLS. 
In general, 20 out of 75 ECLS patients (26.67%) underwent 
heart transplantation, which shows successful integration 
of mechanical circulatory support and heart transplant. 
According to Santise et al (33), 15.7% of heart transplant 
patients develop primary graft failure requiring ECLS sup-
port, with weaning and discharge rates of 84% and 53%, 
respectively, and similar results were reported by Lehmann 
et al (34) and Marasco et al (35). Primary ECLS enhanced 
the pool of potential heart recipients by increasing the 
number of patients at high risk. On the other hand, post-
cardiotomy ECLS was an acceptable last resort option for 
the otherwise hopeless patients with fatal graft failure after 
heart transplantation (35).
In patients requiring ECLS support, approach to cannu-
lation should be personalized and based upon clinical 
condition. For postcardiotomy procedures, intratho-
racic cannulation of the right atrium and ascending 
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aorta seems to be the most appropriate approach. In such 
cases, one should be aware of the possibility of excessive 
postoperative bleeding, which may sometimes mandate 
delayed chest closure with subsequent re-explorations. 
For primary ECLS procedures, the preferable procedure 
is peripheral cannulation. However, such an approach is 
associated with arterial vascular complications including 
ischemic and thrombotic complications. In addition, there 
is the problem of bleeding complications. Peripheral can-
nulation may be performed by percutaneous Seldinger’s 
technique or an open surgical approach. Whenever fea-
sible, we prefer Seldinger’s technique under ultrasound/
Doppler guidance. Ultrasound may additionally help in 
choosing the cannula for arterial cannulation, so that can-
nula size can be adapted to the vessel size. If percutane-
ous femoral cannulation proves to be difficult to perform, 
we regularly apply the open surgical approach, and if the 
femoral artery is noted to be small, 8 cm Dacron graft is 
connected to the femoral artery via termino-lateral anas-
tomosis.
Among patients with peripheral arterial cannulation, we 
observed ischemic complications in 11 cases, 3 out of 
whom developed gangrene with diffuse lower limb isch-
emia. Therefore, it is extremely important to frequently ver-
ify the pulsatility of the anterior and posterior tibial artery 
and to restore the limb perfusion promptly after signs of 
hypoperfusion have been observed. Our rate of vascular 
complications is comparable to the rates in the literature, 
which range between 3.2% and 28% in femoral cannula-
tion sites (36).
Aside from ischemic complications, one should be aware 
of hyperperfusion syndrome presented as an edematous 
limb that is hyperemic and warm to the touch. Hyperper-
fusion syndrome occurs in the limb ipsilateral to the side of 
arterial cannulation. Hyperperfusion syndrome has been 
more frequently associated with ECLS support, with axil-
lary artery side graft technique in up to 24.7% of patients 
(37). This syndrome may cause compartment syndrome, 
leading to secondary ischemic complications that may re-
quire prophylactic fasciotomy or even limb amputation. 
Fortunately, none of our patients had hyperperfusion syn-
drome.
Although associated with considerable complication rates, 
ECLS is a powerful tool for treatment of patients with re-
fractory cardiorespiratory failure. To achieve better results 
and establish ECLS as an integral part of cardiorespira-
tory failure treatment algorithm, multidisciplinary 
management and extensive clinical experience are re-
quired, together with careful patient selection and pooling 
of evidence.
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